Specified serious illness cover in Ireland — why the cheapest policy is rarely the best, and where the wording actually pays

The six-percentage-point spread that does not exist on any other product

On life cover, the five Irish life offices are clustered between 97% and 99%. On specified serious illness, they are spread between 87% and 93%. That is six percentage points on the cover type Irish consumers most often buy alongside their mortgage protection — and it is the only protection product in the Irish market where the office you buy from materially changes the expected outcome.

The 2025 mylife.ie whole-of-market claims report puts the spread at:

The pattern across the disclosing offices is structural, not anecdotal. The same shape appeared in 2024 and the year before. Life cover is paid on death, which is binary — proof of event is the only test. Serious illness pays on a diagnosis that meets a clinical severity threshold defined in the contract. The threshold differs between offices. That is the entire reason the gap exists, and it is the entire reason “cheapest” is the wrong primary lens for this product.

The cheapest policy is rarely the best — and sometimes it is the worst

A specified serious illness premium is a function of mortality and morbidity assumptions, distribution costs, expense loadings and reinsurance. The contract you receive in return is a function of policy wording — the list of conditions covered, the severity thresholds attached to each one, the partial-payment carve-outs, the exclusion structure and the evidence requirements at claim.

These two things are only loosely related. A leaner contract is cheaper to write and cheaper to price. A more claimant-friendly contract — with more conditions, lower severity thresholds, broader partial-payment lists, more modern diagnostic flexibility — costs more to write and more to price. Within the Irish market in 2026, the headline premium difference between the most and least competitive office on a typical 35-year-old non-smoker, mortgage-protection SI rider is rarely more than 15–20%. The contractual difference on the conditions that drive claims is materially larger than that.

Irish Life states publicly that “definition not met is the biggest cause of declined specified illness claims.” New Ireland’s 2024 disclosure broke down 47 declined SI claims as 42 definition-not-met and 5 non-disclosure — nearly nine times as many declines on definition grounds as on disclosure grounds. The 2025 New Ireland disclosure reports an 89% SI paid rate without re-publishing the same numerical decline split, but the order-of-magnitude pattern is unchanged across the market.

Two policies sold by two different offices, on the same life, in the same year, can pay or not pay on identical clinical facts purely because the wording differs. That is the architecture of the product. It is also the reason a price-only comparison routinely sends consumers to a policy with a worse expected outcome than a slightly more expensive alternative.

Cancer is the single most important condition in any Irish SI policy

Cancer accounts for between 55% and 67% of paid specified serious illness claims across the four offices that disclose the breakdown.

A policy that pays well on cancer pays well on most of the SI book. A policy that excludes or limits partial-payment scenarios for early-stage prostate, breast, ductal carcinoma in situ or other site-specific cancers is, by the arithmetic of the cause mix, a materially weaker contract — even if the headline paid rate looks comparable.

The five Irish offices do not write identical cancer definitions. The standard architecture across the market is a full payout on invasive cancers meeting the severity threshold, with partial payouts on a defined list of less advanced cancers. The list, the threshold, and the partial percentages vary by office. The differences are material in three places.

Invasive cancer — the severity carve-outs

Every Irish office covers invasive cancer at full payment, but they do not all draw the line between full and partial at the same point. The same diagnosis can be a full payout at one office and a partial payout at another. Examples:

• One office in the market requires bladder cancer to reach a T2N0M0 stage to qualify for the full payment; lower stages drop to partial.
• Another office excludes Gleason 6 prostate cancer, pre-Binet-A chronic lymphocytic leukaemia, and sub-T2N0M0 thyroid cancer from the full payment — covered instead under the partial-payment heading.
• The treatment of lymphoma and malignant melanoma also varies by office, with some explicitly stating that all forms of lymphoma including non-Hodgkin’s are covered.

A consumer reading a marketing page that says “cancer covered” cannot distinguish between these contracts. The contractual difference is in the definition section of the policy booklet, not the marketing material.

Carcinoma in situ and early-stage cancer

This is where the largest single contractual gap in the Irish SI market sits. Carcinoma in situ — pre-invasive cancer — is the area where Irish offices differ most widely. One office in the market covers carcinoma in situ across roughly twenty sites, including the anus, bile ducts, cervix, colon and rectum, gallbladder, larynx, lung and bronchus, oesophagus, oral cavity, pancreas, renal pelvis and ureter, stomach, testicle, thymus, urinary bladder, uterus, vagina and vulva — and additionally covers desmoid-type fibromatosis, low-malignant-potential GIST, hydatidiform mole, low-grade neuroendocrine tumours, borderline ovarian tumours and primary cutaneous lymphoma.

Other offices cover a much narrower list — typically the principal female sites (breast, cervix, ovary, uterus) and the principal gastrointestinal sites (colon, rectum, oesophagus, stomach, pancreas) — and treat the remainder as not covered or as a smaller partial payment.

For a 38-year-old woman with a family history of breast cancer, the contractual difference in carcinoma-in-situ breadth is the single most important provider-level decision in the Irish market. For a 55-year-old man, it is less material than the invasive-cancer severity threshold and the cardiovascular wording. The cancer “right answer” is not the same for every consumer.

Non-melanoma skin cancer

Non-melanoma skin cancers are excluded from most Irish SI contracts and partially covered by some. This rarely changes a primary claim outcome on its own, but for a consumer with extensive sun exposure, a history of multiple lesions removed, or a strong family history of melanoma, it is worth a contractual look.

Heart attack — where the troponin clause lives

Cardiovascular events are the second-largest condition category across the published SI breakdowns, accounting for roughly 15–20% of paid SI claims across the disclosing offices. Heart attack is the single largest cardiovascular condition.

Every Irish office writes a heart-attack definition built around the same three elements: typical clinical symptoms, ECG changes consistent with myocardial infarction, and a measured rise in cardiac enzymes (typically troponin). The variation is in three places:

The troponin clause. Some offices require a specified numeric troponin threshold and will refuse a claim if the documented troponin level falls below it. At least one office in the market writes the definition without a fixed numeric threshold, requiring only that the troponin level be consistent with a myocardial infarction in the treating clinician’s view. The first formulation is more determinate and easier for the insurer to administer. The second is more claimant-friendly when the clinical picture is unambiguous but the laboratory peak is moderate.

The “and / or” between ECG and imaging. The older market-standard wording requires “typical clinical symptoms AND new ECG changes AND a specified troponin rise.” A more modern approach — used by at least two offices in the Irish market — accepts cardiac CT or MRI imaging as an alternative to ECG changes, allowing for diagnostic flexibility in cases where ECG findings are equivocal.

The exclusions. Heart attacks induced by recreational drug use are excluded by most Irish offices. Stable angina and ischaemic events not meeting the contractual threshold are not covered as heart attacks anywhere in the market.

For the consumer this means: the office whose wording requires symptoms, ECG and troponin all simultaneously is the office most likely to decline an otherwise reasonable cardiology-confirmed MI claim. The office that accepts imaging alternatives and avoids a hard troponin threshold is the office most likely to pay it.

Stroke — “permanent neurological deficit” has replaced “24-hour persistence”

The older market-standard stroke definition required neurological deficit persisting for a minimum number of hours — typically 24. The current dominant wording across the Irish market is stricter on one axis and more permissive on another: it requires the deficit to be permanent rather than persisting for a stated minimum period, and it explicitly excludes transient ischaemic attacks (TIA) and silent infarcts.

Four of the five Irish offices now use a permanent-deficit formulation. One office’s wording continues to reference a fixed minimum persistence period rather than permanence, which is more permissive at the moment of diagnosis but can be problematic where symptoms initially appear severe and then partially resolve.

A separately important point: at least one office in the market covers retinal artery / vein occlusion (“eye stroke”) as a partial payment. The other four do not list it as a separate condition. For consumers with a family history of stroke under age 60, hypertension, atrial fibrillation, or carotid disease, this carve-out matters more than the headline stroke wording.

The decisive variable on stroke is not whether you have stroke cover — every Irish SI policy does — but whether the deficit threshold and the treatment of TIA and eye stroke align with the consumer’s actual risk profile.

Coronary artery bypass and angioplasty — surgical-route restrictions

Coronary artery bypass grafting (CABG) is covered as a full payment across the market. The variation is in the surgical approach the contract recognises:

• Two offices accept any of the standard CABG approaches — median sternotomy, mini-thoracotomy or thoracotomy — and in at least one case mini-thoracotomy and thoracotomy are explicitly listed in the definition.
• At least one office restricts the full payment to median sternotomy, which would exclude an otherwise valid bypass performed via a minimally invasive approach.

This is a small clause with large consequences. As cardiac surgery moves toward less invasive techniques, the proportion of bypasses performed without a full median sternotomy is rising. A policy that requires the older surgical approach is a policy that, by definition, will pay a smaller share of future bypass claims than one that does not.

Coronary angioplasty is handled differently across the market. The dominant approach treats angioplasty as a partial-payment heading. One office in the market is unique in splitting coronary angioplasty into single-vessel and two-or-more-vessel partial payments, giving an earlier-stage payment route for single-vessel disease. Another office writes angioplasty as a full payment when performed on a main coronary artery, with no requirement for multiple vessels. The arithmetic for the consumer: angioplasty is a more common procedure than bypass, and the contractual variation on angioplasty determines payment routes for a meaningful share of cardiac claims that would otherwise produce nothing.

Multiple sclerosis — three definitional points that matter

Multiple sclerosis is the third-largest individual condition category in the Irish SI book after cancer and cardiovascular events. MS definitions across the Irish market vary on three axes that determine claim outcomes.

The persistence period. The historical market-standard wording required symptoms persisting for six months. A more claimant-friendly formulation uses three months, and at least one office in the market writes the definition with no fixed minimum persistence period, requiring only formal diagnostic confirmation.

NMO / Devic’s disease. Neuromyelitis optica spectrum disorder (NMO/Devic’s) is clinically distinct from but related to multiple sclerosis. Two offices in the market expressly include NMO/Devic’s in the MS heading; at least one covers it as a separate Specified Illness; and the supplied wording for another office is silent on it.

“Past or present” symptoms. Most MS definitions require current persisting symptoms at the date of claim. At least one office in the market accepts “past or present” symptoms — meaning a confirmed diagnostic episode followed by remission still triggers a payment provided diagnostic criteria are met.

A consumer with a first-degree relative with MS, MND or Parkinson’s disease should give MS wording disproportionate weight in their provider comparison. The variation is large enough that two otherwise comparable policies can produce opposite outcomes on the same MS diagnosis.

The next tier — Parkinson’s, Alzheimer’s, motor neurone disease, kidney failure

Beyond the “big four” of cancer, heart attack, stroke and MS, a small number of additional headings carry enough claims weight to be worth a wording check before buying.

Parkinson’s disease and Parkinson-plus syndromes

Parkinson’s disease is covered as a full payment across the Irish market, with definitions broadly requiring formal neurological diagnosis and permanent symptoms. The variation sits in two places. First, the exclusion structure: at least one office excludes Parkinson’s where the cause is alcohol or drug-related, which is medically uncommon but worth noting. Second, the treatment of Parkinson-plus syndromes — Progressive Supranuclear Palsy, Multiple System Atrophy, Cortico-Basal Degeneration, Dementia with Lewy Bodies and related conditions. Two offices in the market list five named Parkinson-plus subtypes as a separately covered Specified Illness; at least two do not list them at all. For a consumer with a family history of Parkinson’s under 60, the Parkinson-plus wording is the differential.

Alzheimer’s disease and other dementias

The market-standard Alzheimer’s definition pays on a formal diagnosis with permanent cognitive symptoms. The variation: one office combines Alzheimer’s and other dementias under a single heading; one office lists them as separate Specified Illnesses and pays once across the combined definition; one office’s wording is built around an older formulation that does not explicitly account for non-Alzheimer’s dementias.

Where the policy also offers a “booster” or accelerator benefit on a defined list of severe conditions including Alzheimer’s, the practical payout on an Alzheimer’s diagnosis can be materially larger than the headline sum assured. This kind of benefit exists at one office in the market — typically 200% of cover up to a stated cap — and applies to a defined list including Alzheimer’s, MND, Parkinson’s, blindness, coma, paralysis and major burns.

Motor neurone disease

MND is covered as a full payment across the market. The wording variation is in the explicit inclusion of MND subtypes — ALS, Primary Lateral Sclerosis, Progressive Bulbar Palsy, Progressive Muscular Atrophy, Kennedy’s disease and Spinal Muscular Atrophy. One office in the market lists all six subtypes by name; others use a generic MND heading without subtype enumeration. The generic heading is broader on its face but less determinate at claim time.

Kidney failure requiring dialysis

Covered as a full payment across the market. The variation: one office’s wording requires dialysis to be permanently required, while another writes the definition as dialysis being “necessary.” The difference is most relevant in claims where dialysis is initiated and the underlying renal failure may or may not eventually require transplant.

Major organ transplant

Covered as a full payment across the market. Two offices in the market trigger the payment on inclusion on an official Irish or UK transplant waiting list; others require the transplant surgery to actually have occurred. For consumers with a personal history of organ failure or pending transplant referral, the waiting-list trigger is materially more claimant-friendly.

Third-degree burns, paralysis, coma, blindness

These rarer conditions are universally covered and rarely differ on the question of whether the headline is in the policy. They differ on the threshold (burn percentage, number of limbs affected, hours on life support). For consumers in hazardous occupations or with relevant accident risk, the threshold variation matters; for the typical mortgage-protection buyer, it does not.

What a genuine whole-of-market read looks like in 2026

A consumer buying specified serious illness cover in Ireland in 2026 should expect four things from any process that calls itself a whole-of-market read.

A price comparison at standard premium. This is the easy bit and every Irish broker can do it. It is necessary but never sufficient.

A cancer-definition comparison. Specifically the invasive-cancer severity threshold, the partial-payout list (which sites are covered, at what percentage), the treatment of carcinoma in situ across principal female and gastrointestinal sites, and the handling of non-melanoma skin cancer. This is where the largest single contractual gap in the Irish market sits.

A cardiovascular, stroke and MS wording comparison. Specifically the heart-attack troponin clause and ECG-versus-imaging treatment, the stroke deficit threshold (permanent vs persistence period), the CABG surgical-approach treatment, the MS persistence period and NMO/Devic’s treatment, and the angioplasty single-vessel-versus-two-vessel split where it exists.

A matching of those wording features to the consumer’s own profile. This is the bit a generic comparison cannot do. The right SI contract for a 38-year-old woman with a maternal breast cancer history is materially different from the right contract for a 55-year-old man with treated hypertension and a paternal stroke history — even though both are buying the same product from the same five offices. The wording differences that matter to each consumer are not the same wording differences. A whole-of-market read that ignores the consumer’s profile is half a comparison.

A price comparison without a wording comparison is the most common way an Irish consumer ends up with a paid rate that does not match the marketing. A wording comparison without a profile match is the most common way an Irish consumer ends up paying more than they need to for cover that does not align with their actual risk. mylife.ie publishes the whole-of-market research and conducts the profile match before recommending an office.

The bottom line

Specified serious illness is the only protection product in Ireland where the office you buy from materially changes the expected outcome. The 87–93% spread in 2025 paid rates is real, structural and driven by wording rather than insurer behaviour. The conditions that drive most claims — cancer, heart attack, stroke, MS, CABG, angioplasty, Parkinson’s, Alzheimer’s, MND, kidney failure and the major-organ transplant heading — vary in contractual definition between the five offices in ways that determine whether a specific claim is paid.

Frequently asked